Bladder Urothelial Carcinoma — Trials

Bladder Urothelial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

138 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 60
Recruiting: 23
Ph III recruiting: 3
Growth YoY: —
Industry share: 7%
Top sponsor: National Cancer Institute (NCI)
Termination share: 47.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (21)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02812420	Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery	active not recruiting	Early Phase 1	54	M.D. Anderson Cancer CenterOTHER	1	Sep 14, 2026	clinicaltrials
NCT06204614	Drug Screening Using IMD in Bladder Cancer	enrolling by invitation	Early Phase 1	18	Brigham and Women's HospitalOTHER	1	May 18, 2026	clinicaltrials